Navigation Links
Neurocrine Biosciences To Present At The 25th Annual Roth Conference
Date:3/11/2013

SAN DIEGO, March 11, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin , Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Roth Conference in Laguna Niguel.  

The live presentation takes place on Monday, March 18 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600 or ir@neurocrine.com. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
2. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
4. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
5. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
6. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
8. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. Neurocrine Biosciences Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be a result ... has helped many women become pregnant upon treating their diagnosis. , ... outpatient evaluations. We can provide the necessary information to diagnose and treat ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
Breaking Medicine News(10 mins):